← Open Payments lookup

NPI 1689962730: Open Payments

NPI 1689962730. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,471 in 55 payments from 13 companies in 2025. Trend: 2023 $1,844 · 2024 $1,486 · 2025 $1,471

Food & beverage: $1,438Education: $32
CompanyPaymentsAmount
Amgen Inc.16$377
Novo Nordisk Inc10$300
ABBVIE INC.7$219
AstraZeneca Pharmaceuticals LP5$138
Boehringer Ingelheim Pharmaceuticals, Inc.2$100
Insulet Corporation1$68
Lilly USA, LLC3$52
Supernus Pharmaceuticals, Inc.2$49
Exact Sciences Corporation2$44
PFIZER INC.2$42

Products named: OTEZLA, Wegovy, FARXIGA, REPATHA, BOTOX, JARDIANCE, Ozempic, Omnipod.